Benzamide-Containing Histone Deacetylase Inhibitors With Anticancer Therapeutic Potential

Area of Science:

• Medicinal Chemistry
• Molecular Biology
• Oncology

Background:

• Histone deacetylases (HDACs) regulate crucial cellular processes including gene expression, cell cycle, and apoptosis.
• Dysregulation of HDACs is implicated in cancer development and progression.
• HDAC inhibitors represent a promising class of anticancer agents targeting these enzymes.

Purpose of the Study:

• To review benzamide-containing HDAC inhibitors with anticancer potential.
• To summarize novel benzamide-based HDAC inhibitors developed since 2020.
• To guide future development of effective anticancer therapeutics.

Main Methods:

• Literature review of scientific publications and patents.
• Focus on benzamide derivatives targeting HDACs.
• Analysis of anticancer activity and therapeutic potential.

Main Results:

• Benzamide derivatives effectively inhibit HDACs by chelating zinc ions and interacting with active site residues.
• These inhibitors exhibit anticancer activity through multiple mechanisms, including gene expression regulation and apoptosis induction.
• Recent developments showcase promising benzamide-containing HDAC inhibitors for cancer treatment.

Conclusions:

• Benzamide derivatives are valuable HDAC inhibitors with significant anticancer therapeutic potential.
• Continued research into benzamide-based HDAC inhibitors is crucial for developing novel cancer therapies.
• These compounds offer a rational approach for exploiting HDACs in cancer treatment.